Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Lexicon Pharmaceuticals And 3 Other Stocks Under $2 Insiders Are Buying

Published 13/10/2023, 13:06
© Reuters.  Lexicon Pharmaceuticals And 3 Other Stocks Under $2 Insiders Are Buying
LXRX
-

Benzinga - by Lisa Levin, Benzinga Editor.

The Dow Jones closed lower by around 0.5% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Glatfelter

  • The Trade: Glatfelter Corporation (NYSE: GLT) 10% owner Duane Clint Carlson acquired a total of 236,000 shares an average price of $1.80. To acquire these shares, it cost around 424,800.
  • What’s Happening: Glatfelter entered into an agreement with Ekman & Co. to market Glatfelter's high quality, specialty Abaca pulp exclusively through Ekman's global sales agency platform.
  • What Glatfelter Does: Glatfelter Corporation manufactures and sells a variety of paper and fiber products. The company operates through two segments: Composite Fibers and Airlaid Materials.
Dalrada Financial
  • The Trade: Dalrada Financial Corporation (OTC: DFCO) CEO Brian Bonar acquired a total of 7,300 shares at an average price of $0.25. To acquire these shares, it cost around $1,809.
  • What’s Happening: Dalrada Financial said its subsidiary, Dalrada Technology Spain, entered into an agreement with JBS Consulting, a Paris-based distributor, to build and install as many as 2,300 commercial-grade, energy-efficient heat pumps over the course of five years.
  • What Dalrada Financial Does: Dalrada Financial Corp is a United States-based company engaged in providing financial, insurance, benefit, and business process outsourcing products and services to companies.
Check This Out: Citigroup, JPMorgan And 3 Stocks To Watch Heading Into Friday

Lexicon Pharmaceuticals

  • The Trade: Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) Director Raymond Debbane acquired a total of 1,000,000 shares at an average price of $1.10. The insider spent $1.1 million to buy those shares.
  • What’s Happening: Lexicon Pharmaceuticals said findings from two studies on the cost-effectiveness and budget impact of INPEFA® (sotagliflozin) will be presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting on October 16-19, 2023, in Orlando, Florida.
  • What Lexicon Pharmaceuticals Does: Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases.
Augusta Gold
  • The Trade: Augusta Gold Corp. (OTC: AUGG) Executive Chairman Richard Warke acquired a total of 15,000 shares at an average price of $0.51. The insider spent around $7,600.
  • What’s Happening: The company’s stock gained around 9% over the past month.
  • What Augusta Gold Does: Augusta Gold Corp is an exploration-stage company. The company is primarily engaged in the acquisition and exploration of gold properties.

Don’t forget to check out our premarket coverage here

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.